Thermo Fisher Scientific has introduced the Gibco Efficient-Pro Medium (+) Insulin, a cutting-edge medium crafted to enhance titers, maximize productivity, and boost the performance of insulin-dependent CHO cell lines.
The Efficient-Pro Medium (+) Insulin serves as a valuable addition to Thermo Fisher’s existing Efficient-Pro medium and feed system, aimed at delivering optimized growth and productivity for insulin-dependent CHO cell lines while streamlining workflow and handling processes.
This innovative medium is tailored for Biopharma Manufacturers, Biotechnology Companies, and Contract Development and Manufacturing Organizations (CDMOs) focusing on CHO-Based Therapeutics. It offers enhanced protein yield, optimized productivity for insulin-dependent CHO cell lines commonly utilized in monoclonal antibody and biosimilar production, and simplifies preparation processes and logistics.
Efficient-Pro Medium (+) Insulin provides a host of benefits for protein therapeutic developers, such as simplifying process development by ensuring consistent, high-performance growth and production conditions with reduced variability.
Sara Henneman, the vice president and general manager of Thermo Fisher Scientific’s cell culture and cell therapy business, emphasized the significance of this advancement in bioprocessing technology. By integrating the AGT format and an AOF formulation, Thermo Fisher addresses critical industry challenges and provides customers with a reliable, high-performance solution through Efficient-Pro Medium (+) Insulin.
The design of Efficient-Pro Medium (+) Insulin aims to eliminate the need for manual insulin supplementation, streamlining the bioproduction process and enabling customers to scale up rapidly, adapt to evolving project requirements, and expedite the delivery of life-changing therapies to patients.
Andy Campbell, senior director of research and development at Thermo Fisher Scientific, highlighted the company’s commitment to removing barriers in bioproduction and supporting customers in achieving more. The innovation brought by Efficient-Pro Medium (+) Insulin empowers customers to streamline processes, minimize risks, and expedite the market introduction of new treatments efficiently.
Thermo Fisher’s dedication to innovation and patient outcomes is underscored by the Efficient-Pro Medium (+) Insulin, providing tools and support to accelerate processes and enhance efficiency in bringing groundbreaking therapies to the market.
Takeaways:
– Thermo Fisher Scientific’s Efficient-Pro Medium (+) Insulin revolutionizes bioprocessing by enhancing productivity and streamlining workflows.
– The medium offers optimized growth and productivity for insulin-dependent CHO cell lines, benefiting biopharma manufacturers and biotechnology companies.
– Efficient-Pro Medium (+) Insulin simplifies process development and eliminates the need for manual insulin supplementation, enabling rapid scaling and efficient delivery of therapies.
– Thermo Fisher Scientific’s commitment to innovation and patient outcomes is exemplified through the development of Efficient-Pro Medium (+) Insulin.
Tags: biopharma, process development, cell therapy, formulation, cell culture, scale up
Read more on medicaldialogues.in